The start of the 40-subject PK trial of MED2002 (Eroxon®) is in line with expectations. The trial will provide additional safety and tolerability data for Eroxon® and inform the choice of dose range for the subsequent Phase III programme. Meanwhile we look forward to a first out-licensing agreement for Eroxon®, currently expected before the start of Phase III in H1 2018. We continue to view Eroxon® as a differentiated product with significant commercial potential in both prescription and, over t ....
29 Nov 2017
N+1 Singer - Futura Medical - Good progress in Eroxon® licensing discussions; PK trial underway
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Futura Medical - Good progress in Eroxon® licensing discussions; PK trial underway
Futura Medical plc (FUM:LON) | 39.4 0.2 1.5% | Mkt Cap: 118.8m
- Published:
29 Nov 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The start of the 40-subject PK trial of MED2002 (Eroxon®) is in line with expectations. The trial will provide additional safety and tolerability data for Eroxon® and inform the choice of dose range for the subsequent Phase III programme. Meanwhile we look forward to a first out-licensing agreement for Eroxon®, currently expected before the start of Phase III in H1 2018. We continue to view Eroxon® as a differentiated product with significant commercial potential in both prescription and, over t ....